Metabolic Syndrome, Insulin Resistance and Adiponectin
Level in Patients with
Chronic Hepatitis C
Full Article (PDF file)
Mircea Grigorescu1, Corina Radu1, Dana
Crişan1, Mircea Dan Grigorescu1, Alexandru
Şerban2, Dana Neculoiu3, Margareta Rusu2,
1) 3rd Medical Clinic, University of Medicine and Pharmacy, Cluj-Napoca;
2) Emergency Universitary Hospital, Cluj-Napoca;
3) Emergency County Hospital, Brasov, Romania
Aims. To assess insulin resistance and adiponectin
profile in patients with chronic hepatitis C (CHC), according
to the presence or absence of metabolic syndrome (MS).
Patients and methods. One hundred and fifty-two
patients with histologically proven CHC, genotype I were prospectively
studied. Parameters of MS according to the IDF criteria were evaluated.
Insulin resistance was established by homeostasis model assessment
(HOMA-IR]. An index = 2.0 was designated as IR and = 4 as prediabetic
state. Serum adiponectin levels were measured by ELISA.
Results. MS was found in 61.48% of cases. HOMA-IR
was significantly higher in patients with CHC and MS vs those
without MS (7.88±1.11 vs 4.29 ±0.5, p=0.023]. Adiponectin
levels had an inverse behaviour (9,946.1 ±5,811 ng/ml vs
13,215.5 ± 815.5 ng/ml, p< 0.001]. By multiple linear
regression analysis the independent predictors associated with
HOMA-IR = 4 in patients with CHC and MS were visceral obesity,
adiponectin levels, activity and degree of steatosis. Only visceral
obesity and HOMA-IR were independently associated with adiponectin.
A significant negative correlation was established between adiponectin
and insulin (r = - 0.169, p=0.003] and between adiponectin and
HOMA-IR (r = - 0.188, p=0.02].
Conclusions. CHC with MS was associated with
a higher insulin resistance and lower adiponectin level. Adiponectin
level and insulin resistance were significantly correlated.
Chronic hepatitis C - metabolic syndrome - insulin resistance
- serum adiponectin